Results 141 to 150 of about 1,107,385 (201)

Potential drug-drug interactions and 30-day mortality in ICU patients with bloodstream infection: a single-center retrospective study. [PDF]

BMC Infect Dis
Guo P, Zhang S, Huang Z, Zhu J, Zhang W.
europepmc   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

CYP2C8-Mediated Drug-Drug Interactions and the Factors Influencing the Interaction Magnitude. [PDF]

Drug Des Devel Ther
Zhu LL, Yu LY, Wang YH, Zhou Q.
europepmc   +1 more source

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions. [PDF]

Front Pharmacol
Cronin JM, Yu AM.
europepmc   +1 more source

Burden and Determinants of Drug-Drug Interactions at Hospital Discharge: Warfarin as a Model for High-Risk Medication Safety. [PDF]

Clin Pract
Methaset K, Jedsadayanmata A.
europepmc   +1 more source

Managing Drug-Drug Interactions Involving the Non-Prescription Opioid Loperamide Through Physiologically Based Pharmacokinetic Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
Zhou Z, Ainslie GR, Li M, Dinh J, Zamek-Gliszczynski MJ, Zhao P, Paine MF.   +6 more
europepmc   +1 more source

Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds. [PDF]

Malar J
Tipthara P, Kullasakboonsri R, Kobylinski KC, Tarning J.   +3 more
europepmc   +1 more source

Drug-drug interactions between sex hormones and analgesics linked to thromboembolic events: an FDA adverse event reporting system analysis. [PDF]

Front Pharmacol
Yamazaki S, Onda K, Masuyama K.
europepmc   +1 more source